No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
SHANGHAI PHARMACEU To Go Ex-Dividend On July 19th, 2024 With 0.282 USD Dividend Per Share
July 9th (Eastern Time) - $SHANGHAI PHARMACEU(SHPMY.US)$ is trading ex-dividend on July 19th, 2024.Shareholders of record on July 19th, 2024 will receive 0.282 USD dividend per share on September 11
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Sh Pharma (601607.SH): Application for listing approval of active pharmaceutical ingredient Citrate Tofacitinib was approved.
Sh Pharma (601607.SH) announced on July 8 that its wholly-owned subsidiary Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd. has received the "Approval Notice for Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for the raw material of Citrate Tofacitinib. The pharmaceutical has been approved for production. Citrate Tofacitinib is mainly used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, developed by Pfizer. The formulation was first launched in the United States in 2012.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Sh Pharma (02607): The exercise period for stock options is from July 8 to July 22.
Sh Pharma (02607) has announced the initial grant of stock options for its 2019 A-share stock option incentive plan.
No Data